A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase

Kenneth J Finn1, Scott E Martin2, Jeff Settleman3

  • 1Calico Life Sciences LLC, South San Francisco, California.

Cancer Research
|October 24, 2019
PubMed

Insights

Modeling acquired drug resistance in cancer cells using a high-dose, single-step selection method revealed distinct resistance mechanisms not found with conventional gradual exposure. This highlights how selection methods impact identified cancer drug resistance pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Acquired drug resistance limits the long-term effectiveness of molecularly targeted cancer therapies.
  • Identifying resistance mechanisms is crucial for developing strategies to overcome treatment evasion.

Purpose of the Study:

  • To investigate if a single-step, high-dose drug selection method identifies different cancer drug resistance mechanisms compared to conventional gradual exposure.
  • To characterize novel resistance mechanisms to MET kinase inhibitors.

Main Methods:

  • Exposing a single clonally derived cancer cell line to a continuous, high concentration of MET kinase inhibitor.
  • Isolating and analyzing resistant clones to determine the underlying mechanisms of acquired resistance.

Main Results:

  • Three distinct resistance mechanisms were identified: upregulation of FGF3 or HBEGF, and increased MAPK signaling via a BRAF V600E mutation.
  • These mechanisms were not detected using the conventional gradual drug concentration increase (ramp-up) method in prior studies with the same cell line.
  • The selection scheme significantly influenced the types of resistance mechanisms identified.

Conclusions:

  • The method used to model acquired resistance in cell culture critically impacts the identification of specific resistance mechanisms.
  • Employing diverse selection strategies, including single-step high-dose exposure, is essential for a comprehensive understanding of cancer drug resistance.
  • This study underscores the need for careful consideration of experimental design in resistance modeling to uncover all potential evasion pathways.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K